ArticleInternational review of neurobiology2022
Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism.
Article in International review of neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Meta-analysis of the serum/plasma proteome identifies significant associations between COVID-19 with Alzheimer's/Parkinson's diseases.Journal of neurovirology · 2024Pooled it
- A systematic review and meta-analysis on the effect of virtual reality-based rehabilitation for people with Parkinson's disease.Journal of neuroengineering and rehabilitation · 2023Pooled it
- Effects of a Four-Strain Probiotic on Gut Microbiota, Inflammation, and Symptoms in Parkinson's Disease: A Randomized Clinical Trial.Movement disorders : official journal of the Movement Disorder Society · 2025Trial
- Alpha-synuclein at the crossroads of host-virus interactions: immunological roles beyond the nervous system.Journal of virology · 2026Review
- Clinical Characteristics of Patients Initially Suspected of Long COVID: A Case Series From a Specialized Outpatient Clinic.Journal of general and family medicine · 2026Article
- The Effect of SARS-COV-2 Protein Fragments on the Dimerization of α-Synuclein.ACS chemical neuroscience · 2025Article
- Circadian re-set repairs long-COVID in a prodromal Parkinson's parallel: a case series.Journal of medical case reports · 2024Article
- Brain-Region-Specific Differences in Protein Citrullination/Deimination in a Pre-Motor Parkinson's Disease Rat Model.International journal of molecular sciences · 2024Article
- SARS-CoV-2 Spike Protein S1 Domain Accelerates α-Synuclein Phosphorylation and Aggregation in Cellular Models of Synucleinopathy.Molecular neurobiology · 2024Article
- No genetic link between Parkinson's disease and SARS-CoV-2 infection: a two-sample Mendelian randomization study.Frontiers in neurology · 2024Article
- Intracellular peptides in SARS-CoV-2-infected patients.iScience · 2023Article
- SARS-CoV-2 and Parkinson's Disease: A Review of Where We Are Now.Biomedicines · 2023Review
- Meta-Analysis of the Mechanisms Underlying COVID-19 Modulation of Parkinson's Disease.International journal of molecular sciences · 2023Article
- SARS-COV-2 spike protein fragment eases amyloidogenesis of α-synuclein.The Journal of chemical physics · 2023Article
- SARS-COV-2 Spike Protein Fragment eases Amyloidogenesis of α-Synuclein.bioRxiv : the preprint server for biology · 2023Article
- Parkinson's Disease, SARS-CoV-2, and Frailty: Is There a Vicious Cycle Related to Hypovitaminosis D?Brain sciences · 2023Review
- Dopamine Transmission Imbalance in Neuroinflammation: Perspectives on Long-Term COVID-19.International journal of molecular sciences · 2023Review
- Article
- Changes in Apathy, Depression, and Anxiety in Parkinson's Disease from before to during the COVID-19 Era.Brain sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Coronavirus Disease 2019 (Covid-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has led to unprecedented challenges for the delivery of healthcare and has had a clear impact on people with chronic neurological conditions such as Parkinson's disease (PD). Acute worsening of motor and non-motor symptoms and long-term sequalae have been described during and after SARS-CoV-2 infections in people with Parkinson's (PwP), which are likely to be multifactorial in their origin. On the one hand, it is likely that worsening of symptoms has been related to the viral infection itself, whereas social restrictions imposed over the course of the Covid-19 pandemic might also have had such an effect. Twenty cases of post-Covid-19 para-infectious or post-infectious parkinsonism have been described so far where a variety of pathophysiological mechanisms seem to be involved; however, a Covid-19-induced wave of post-viral parkinsonism seems rather unlikely at the moment. Here, we describe the interaction between SARS-CoV-2 and PD in the short- and long-term and summarize the clinical features of post-Covid-19 cases of parkinsonism observed so far.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.